日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

联合CRISPR和转座子技术优化通用同种异体CAR-T细胞治疗急性髓系白血病

Cristina Calviño, Candela Ceballos, Ana Alfonso, Patricia Jauregui, Maria E Calleja-Cervantes, Patxi San Martin-Uriz, Paula Rodriguez-Marquez, Angel Martin-Mallo, Elena Iglesias, Gloria Abizanda, Saray Rodriguez-Diaz, Rebeca Martinez-Turrillas, Jorge Illarramendi, Maria C Viguria, Margarita Redondo,

In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

体内 CRISPR-Cas9 抑制肝脏 LDH 治疗原发性高草酸尿症

Rebeca Martinez-Turrillas, Angel Martin-Mallo, Saray Rodriguez-Diaz, Natalia Zapata-Linares, Paula Rodriguez-Marquez, Patxi San Martin-Uriz, Amaia Vilas-Zornoza, María E Calleja-Cervantes, Eduardo Salido, Felipe Prosper, Juan R Rodriguez-Madoz

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

CRISPR/Cas9介导的乙醇酸氧化酶基因敲除是治疗I型原发性高草酸尿症的一种有效且安全的疗法。

Nerea Zabaleta ,Miren Barberia ,Cristina Martin-Higueras ,Natalia Zapata-Linares ,Isabel Betancor ,Saray Rodriguez ,Rebeca Martinez-Turrillas ,Laura Torella ,Africa Vales ,Cristina Olagüe ,Amaia Vilas-Zornoza ,Laura Castro-Labrador ,David Lara-Astiaso ,Felipe Prosper ,Eduardo Salido ,Gloria Gonzalez-Aseguinolaza ,Juan R Rodriguez-Madoz

Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome

针对 G9a 和 DNMT1 的可逆双重抑制剂可改善人类 iPSC 衍生,增强 MET 并促进转录因子与基因组的结合

Juan Roberto Rodriguez-Madoz, Edurne San Jose-Eneriz, Obdulia Rabal, Natalia Zapata-Linares, Estibaliz Miranda, Saray Rodriguez, Angelo Porciuncula, Amaia Vilas-Zornoza, Leire Garate, Victor Segura, Elizabeth Guruceaga, Xabier Agirre, Julen Oyarzabal, Felipe Prosper